INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript
Operator: Greetings. And welcome to the INmune Bio First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Inmune Bio Inc. (INMB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Praetorian Capital Harris Kupperman | 865,000 | $6,755,650 | +7% | 2.92% |
| 2. | Millennium Management Israel Englander | 241,248 | $1,884,147 | -18% | 0% |
| 3. | Rhenman & Partners Asset Management Henrik Rhenman | 178,284 | $1,392,398 | 0.16% | |
| 4. | 3,904 | $1,032,085 | +393% | 0.45% | |
| 5. | Citadel Investment Group Ken Griffin | 101,511 | $792,801 | +95% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.29 | 10,000 | $52,868.00 | 1,285,869 | 2024-09-30 | Filing | |
| $6.38 | 15,380 | $98,047.50 | 1,554,106 | 2024-09-12 | Filing | |
| $6.38 | 7,690 | $49,023.75 | 1,275,869 | 2024-09-12 | Filing | |
| $7.27 | 5,000 | $36,350.00 | 71,603 | 2024-06-25 | Filing | |
| $8.32 | 18,028 | $149,992.96 | 1,268,179 | 2024-04-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.01 | 10,000 | $110,085.00 | 82,187 | 2023-07-12 | Filing | |
| $20.00 | 701 | $14,020.00 | 1,472,793 | 2021-11-03 | Filing | |
| $20.00 | 1,025 | $20,500.00 | 1,219,158 | 2021-11-03 | Filing | |
| $20.00 | 3,626 | $72,520.00 | 1,490,674 | 2021-11-03 | Filing | |
| $20.00 | 6,517 | $130,340.00 | 1,494,300 | 2021-10-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 948,362 | $7,406,707 | 0% | |
| 2. | 826,613 | $6,455,848 | 0% | |
| 3. | 382,041 | $2,983,740 | 0% | |
| 4. | 364,862 | $2,849,867 | 0% | |
| 5. | 236,128 | $1,844,160 | 0% |
News See All
INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the INmune Bio’s. 2024 Fourth Quarter and Full Year Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions].
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025
The healthcare sector is staging a comeback so far in 2025 after two years of underperformance. These stocks could get even hotter due to AI.
INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
INmune Bio, Inc. (NASDAQ:INMB) Q2 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the INmune Bio Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript
Operator: Greetings and welcome to the INmune Bio First Quarter 2024 Earnings Call. At the end of the presentation, there will be a question-and-answer session.
INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript
INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58.
INmune Bio, Inc. (NASDAQ:INMB) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
15 Most Shorted Stocks That Are Loved By Analysts
In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts.